Stockwinners Market Radar for July 15, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:04 EDT Cathie Wood's ARK Investment buys 98.2K shares of PacBio today

19:48 EDT Nvidia CEO sells $31.3M in common stock as part of option exercise - In a regulatory filing, Nvidia disclosed that its CEO Jen Hsun Huang sold 240K shares of common stock on July 11th as part of option exercise in a total transaction size of $31.3M.

17:47 EDT Finance of America announces date for reverse stock split - Finance of America expects its intended 1-for-10 reverse stock split of its outstanding shares of Class A Common Stock, previously disclosed on June 27, to be effective as of July 25. The company's Class A Common Stock is expected to begin trading on a split-adjusted basis on the NYSE under the existing symbol when the market opens on July 26. The new CUSIP number for the company's Class A Common Stock following the reverse stock split will be 31738L 206. With respect to the company's warrants, every ten shares of Class A Common Stock that may be purchased pursuant to the exercise of warrants prior to the effective time represent one share of Class A Common Stock that may be purchased pursuant to such warrants following the effective time. The exercise price for each warrant following the Effective Time equals the product of ten multiplied by the exercise price prior to the Effective Time. Accordingly, the exercise price for the Company's public warrants will be $115. The CUSIP number for the company's warrants will not change. The reverse stock split is primarily intended to increase the per share trading price of Finance of America's Class A Common Stock in order to meet the NYSE's price criteria for continued listing.

17:36 EDT Delta Air Lines director buys $439K in common stock - In a regulatory filing, Delta Air Lines disclosed that its director Willie Chiang bought 10K shares of common stock on July 12th in a total transaction size of $439K.

17:05 EDT Bassett Furniture says business operations disrupted by IT systems breach - In a regulatory 8-K filing, the company stated: "On July 10, 2024, Bassett Furniture detected unauthorized occurrences on a portion of its information technology systems. Upon detecting the unauthorized occurrences, the Company immediately began taking steps to contain, assess and remediate the incident, including beginning an investigation, activating its incident response plan, and shutting down some systems. The threat actor disrupted the Company's business operations by encrypting some data files. As a result of the Company's containment measures, which included shutting down some systems, the Company has not been, and, as of the date of this Report is not operating its manufacturing facilities. The Company's retail stores and e-commerce platform are open, and customers are able to place orders and purchase available merchandise; however, the Company's ability to fulfill orders is currently impacted. The Company is working to bring the impacted portions of its IT systems back online and implement workarounds for certain offline operations with the aim of reducing disruption to its ability to serve its retail, e-commerce and wholesale customers. At this time, the Company does not believe personal information from consumers was compromised. The Company continues to work diligently to respond to and mitigate the impact from the incident. As the investigation of the incident is ongoing, the full scope, nature and impact of the incident are not yet known. As of the date of this filing, the incident has had and is reasonably likely to continue to have a material impact on the Company's business operations until recovery efforts are completed. The Company has not yet determined whether the incident is reasonably likely to materially impact the Company's financial condition or results of operations."

17:02 EDT Amazon.com executive chair Jeff Bezos sells $80.8M in common stock - In a regulatory filing, Amazon.com disclosed that its Executive Chair Jeff Bezos sold 404K shares of common stock on July 11th in a total transaction size of $80.8M.

16:54 EDT TransUnion CFO Cello sells 12,865 common shares - In a regulatory filing, TransUnion CFO Todd Cello disclosed the sale of 12,865 common shares of the company on July 12 at a price of $80 per share.

16:31 EDT SK Telecom makes $200M preferred equity investment in SGH - SGH (SGH) announced that SK Telecom (SKM) is making a $200M preferred equity investment in SGH. SGH plans to use the capital from SKT's investment to enhance SGH's capabilities and add to the Company's financial flexibility as SGH further expands the scope and scale of its Penguin Solutions branded end-to-end AI factory offerings. SKT and SGH also intend to leverage their complementary capabilities to enhance customer offerings in the development of differentiated global end-to-end AI factory and data center solutions and services, advanced memory market products and services, and NPU-based AI edge servers. "We are thrilled to have SKT as a strategic investor," said Mark Adams, CEO of SGH. "Today's announcement is a testament to Penguin Solutions' capabilities in the deployment of AI factories at scale through our systems, software, and managed services suite of solutions. We look forward to executing on strategic collaboration opportunities with the SKT team and believe they will create value for our respective stakeholders."

16:17 EDT FB Financial reports Q2 net interest margin 3.57% vs. 3.40% last year - The Company experienced net charge-offs of $0.6 million in the second quarter of 2024, representing annualized net charge-offs of 0.02% of average loans HFI, which compares to annualized net charge-offs of 0.02% in the prior quarter and annualized net charge-offs of 0.03% in the second quarter of 2023.

16:17 EDT UpHealth announces CEO transition and organizational changes - UpHealth announced the appointment of of Jay Jennings, currently the company's CFO, to serve as Acting CEO, replacing Martin Beck, who resigned as CEO effective July 10. Beck also resigned from his position as a Class I director of the company effective July 10. On July 11, the Board determined that it would not appoint any successor to fill the vacancy created by Beck's resignation as a Class I director at this time. In addition, the Board promoted Lisa Fluxman to President of TTC Healthcare, and re-affirmed the position of Jeremy Livianu as the Chief Legal Officer and Secretary of UpHealth.

16:12 EDT HashiCorp vote to approve transaction with IBM - HashiCorp (HCP) announced that at the Special Meeting of Stockholders held earlier based on preliminary voting results, HashiCorp stockholders voted to approve the acquisition of HashiCorp by IBM (IBM)."We are pleased to achieve this important milestone towards officially joining IBM and thank our stockholders for their support," said Dave McJannet, HashiCorp chief executive office. "By uniting two leading technology businesses with complementary visions, this transaction provides an incredible opportunity to accelerate HashiCorp's mission." The final voting results of the Special Meeting will be filed as part of a Form 8-K with the U.S. Securities and Exchange Commission. The transaction is expected to close by the end of 2024, subject to the remaining regulatory approvals and other customary closing conditions under the merger agreement.

16:09 EDT Repligen says unauthorized third party accessed files in its info systems - According to a regulatory filing, on July 9, 2024, Repligen Corporation discovered that an unauthorized third party had accessed certain files on the Company's information systems. Upon this discovery, the Company immediately activated response procedures to investigate, contain, and remediate the incident and also notified law enforcement, in accordance with the Company's established protocols. The Company has engaged external cybersecurity experts to assist with the investigation and other response activities. As of the date of this report, other than the Company's response and remediation activities, the incident has not had an impact on the Company's business or operations. The Company's ability to serve customers has also not been impacted, and its information systems remain operational and undisrupted. Further, the Company does not anticipate that this incident will have a material impact on its financial condition or results of operations. While the Company believes it has contained the incident and that no systems were encrypted by malware, it continues to investigate this matter to determine the full extent of the impact on the Company, including what, if any, regulatory and legal notifications the Company will need to make as a result of this matter.

16:06 EDT Accel Entertainment to acquire Fairmount for roughly $35M - Accel Entertainment and Fairmount Holdings announced that the companies have entered into an agreement for Accel to acquire Fairmount, the owner of FanDuel Sportsbook & Horse Racing, for total consideration of approximately $35 million (based on a 20-day trailing average), payable to the sellers as 3.45 million shares of Accel Class A-1 common stock. During the year ended December 31, 2023, Fairmount generated $29 million of revenue and modest Adjusted EBITDA. Accel plans to invest $85 - $95 million (over and above the purchase price) to fund temporary and then permanent casino construction and modest track investments. Accel's five-year forecast suggests an Adjusted EBITDA potential of $20 to $25 million and over 75% free cash flow conversion - pointing to a compelling cash flow return on capital. The asset will be the cornerstone in a local gaming platform that builds on Accel's capabilities and strengths as a leading route-based operator. The all-equity offer for Fairmount of 3.45 million shares of Accel Class A-1 common stock represents a total enterprise value of approximately $35 million, based on a trailing 20-day average. Accel expects the acquisition to accelerate its long-term financial model with high return growth at accretive margins. Upfront buildout costs will be funded from Accel's existing revolver facility. The closing of the transaction is subject to customary closing conditions and customary approvals from the Illinois Racing Board and the Illinois Gaming Board. Closing is expected in the fourth quarter of 2024. The transaction has been approved by Accel's Board of Directors and the Board of Directors and shareholders of Fairmount Holdings. Wells Fargo acted as exclusive financial advisor and Lewis Rice LLC acted as legal counsel to Fairmount Holdings in connection with the transaction. McDermott Will & Emery LLP acted as legal counsel to Accel Entertainment in the transaction.

16:01 EDT OFS Credit estimates NAV per share of $7.15-$7.25 as of June 30, 2024 - OFS Credit Company announced the following net asset value estimate as of June 30, 2024. Management's unaudited estimate of the range of its NAV per share of our common stock as of June 30, 2024 is between $7.15 and $7.25.

14:21 EDT AMCON Distributing trading resumes

13:42 EDT Nvidia CEO Huang, Meta CEO Zuckerberg to discuss AI at SIGGRAPH conference - Nvidia (NVDA) founder and CEO Jensen Huang and Meta (META) founder and CEO Mark Zuckerberg will hold a public fireside chat on Monday, July 29, at the 50th edition of the SIGGRAPH graphics conference in Denver. The two leaders will discuss the future of AI and simulation and the pivotal role of research at SIGGRAPH, which focuses on the intersection of graphics and technology. Before the discussion, Huang will also appear in a fireside chat with WIRED senior writer Lauren Goode to discuss AI and graphics for the new computing revolution. Reference Link

12:18 EDT OneStream launches roadshow for proposed IPO of 24.5M class A shares - OneStream (OS) announced that it has launched the roadshow for its proposed initial public offering of 24,500,000 shares of its Class A common stock, 18,054,333 shares of which are being offered by OneStream and 6,445,667 shares of which are being offered by certain existing stockholders. In addition, OneStream intends to grant the underwriters a 30-day option to purchase up to an additional 3,675,000 shares of Class A common stock from OneStream at the initial public offering price, less underwriting discounts and commissions. The initial public offering price is expected to be between $17.00 and $19.00 per share. OneStream intends to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol "OS." OneStream intends to use a portion of the net proceeds to it from this offering to purchase newly issued common units of OneStream Software LLC, of which OneStream will be the sole manager. OneStream intends to use the remaining net proceeds to purchase common units of OneStream Software LLC and shares of Class C common stock from certain of its existing stockholders in a synthetic secondary transaction at a purchase price per unit equal to the initial public offering price per share of Class A common stock, net of underwriting discounts and commissions. OneStream will not receive any proceeds from the sale of shares by the selling stockholders. Morgan Stanley (MS), J.P. Morgan (JPM) and KKR (KR) are acting as lead book-running managers for the proposed offering. BofA Securities, Citigroup and Guggenheim Securities are acting as book-running managers and Raymond James, Scotiabank, Truist Securities, BTIG, Needham & Company, Piper Sandler, TD Cowen and Wolfe Nomura Alliance are acting as additional book-running managers. Amerivet Securities, Blaylock Van, LLC, Cabrera Capital Markets LLC, Drexel Hamilton and Loop Capital Markets are acting as co-managers for the proposed offering.

12:12 EDT Veeva names Brian Van Wagener CFO after transition period - Veeva Systems earlier today announced that Brian Van Wagener will become the company's chief financial officer following a 60-day transition with Veeva board member and interim CFO, Tim Cabral. Cabral will remain on the Veeva board. In his more than five years at Veeva, Van Wagener held multiple executive positions as a member of the company's leadership team, including vice president of global sales operations and chief of staff to the CEO.

12:03 EDT Duke Energy raises quarterly dividend by 2c to $1.045 per share - Duke Energy declared a quarterly cash dividend on its common stock of $1.045 per share, an increase of 2c. This dividend is payable on September 16, to shareholders of record at the close of business on August 16.

12:00 EDT Aeva Technologies rises 10.6% - Aeva Technologies is up 10.6%, or 32c to $3.35.

12:00 EDT Sunnova Energy falls -8.9% - Sunnova Energy is down -8.9%, or -69c to $7.00.

12:00 EDT Macy's falls -12.9% - Macy's is down -12.9%, or -$2.47 to $16.62.

10:32 EDT Cyngn trading resumes

10:27 EDT Trimble extends partnership with Esri for GIS software collaboration - Trimble announced the extension of their long-standing strategic partnership with Esri to enhance collaboration in geographic information system software, location intelligence and mapping. The ongoing effort advances methods to optimize processes, support decision making and automate workflows that enable greener infrastructure planning, construction and operations for mutual customers.

10:05 EDT Midland States Bank partners with Transend - Transend announced its strategic partnership with Midland States Bank. Through this partnership, Transend and Midland will take an innovative approach to traditional financing, offering dynamic payment solutions that empower suppliers to offer instant access to working capital at the point of commerce. Transend and Midland share a partner-centric vision and through this strategic alliance, the companies will play a critical role in helping suppliers nationwide drive loyalty, increase sales, and accelerate accounts receivable with their commercial customers.

10:02 EDT Sunnova Energy falls -14.1% - Sunnova Energy is down -14.1%, or -$1.08 to $6.60.

10:01 EDT Macy's falls -15.7% - Macy's is down -15.7%, or -$2.99 to $16.10.

10:01 EDT Bitcoin Investment Trust rises 9.2% - Bitcoin Investment Trust is up 9.2%, or $4.70 to $55.84.

10:00 EDT Sturm Ruger rises 11.6% - Sturm Ruger is up 11.6%, or $4.78 to $46.14.

09:48 EDT Geo Group rises 9.0% - Geo Group is up 9.0%, or $1.44 to $17.38.

09:48 EDT Daqo New Energy falls -6.5% - Daqo New Energy is down -6.5%, or -$1.10 to $15.79.

09:47 EDT Macy's falls -13.8% - Macy's is down -13.8%, or -$2.63 to $16.46.

09:45 EDT Prenetics Global Ltd trading resumes

09:37 EDT Goldman engaging with regulators to better understand stress capital buffer

09:35 EDT Inspire Veterinary Partners Inc trading halted, volatility trading pause

09:34 EDT Goldman Sachs expects to exceed $50B in alternative fundraising this year

09:33 EDT Goldman Sachs CEO Solomon: No place in our country for violence - Comments taken from Q2 earnings conference call.

09:29 EDT BlueRiver Acquisition Corp trading halted, news dissemination

09:25 EDT Hyperfine highlights data from ACTION PMR on Swoop as promising tool for stroke - Hyperfine highlights the results from a multi-site observational study that showed the value of using Swoop system images to quickly assess stroke patients and help guide physicians making critical treatment decisions. This publication marks the first to include a subset of ACTION PMR study data and shows encouraging results. The study, entitled "Diffusion-Weighted Imaging and Fluid-Attenuated Inversion Recovery Mismatch on Portable, Low-Field Magnetic Resonance Imaging Among Acute Stroke Patients," will be published in the August 2024 issue of the Annals of Neurology. It included 71 patients and was conducted by a team from several institutions, including Massachusetts General Hospital and the University at Buffalo, two of the centers in the ACTION PMR study. "Our goal is to assess whether portable, ultra-low-field MRI can be used as a tissue clock to characterize acute stroke, which has the potential to inform treatments and improve outcomes. Thus far, we have convincing data on FLAIR showing that this is, in fact, the case," said Dr. Taylor Kimberly, Chief of the Division of Neurocritical Care at Massachusetts General Hospital, one of the lead authors

09:19 EDT Dolphin Entertainment acquires PR agency Elle Communications - Dolphin Entertainment has acquired Elle Communications, a PR agency specializing in social and environmental impact for a client roster of mission-centered brands, nonprofits and philanthropic foundations, social enterprises, CSR teams, sustainably and ethically-made products, activists, and leaders who are making the world a better place. Elle Communications will become a division of entertainment PR powerhouse 42West, while joining other preeminent PR firms Shore Fire Media, and The Door, influencer marketing agency The Digital Department, and celebrity booking and event agency Special Projects in the Dolphin Entertainment collection of specialty agencies. Founded in 2008 by Danielle Finck, with offices in Los Angeles and New York, Elle Communications was an early pioneer in social and environmental impact PR. Danielle Finck and Silvie Snow-Thomas will lead Elle Communications, with its entire senior leadership team and staff welcomed into Dolphin Entertainment.

09:15 EDT Camber Energy announces update on ESG carbon capture system - Camber Energy shared the most recent announcement from ESG Clean Energy advising that ESG's carbon capture system has achieved capturing 100% of the CO2 from a combustion exhaust stream, making it possible for any internal combustion engine - big or small - to have no carbon dioxide emissions. ESG's patented system consists of a two-step process: first removing the water from the exhaust and then capturing the CO2. Drying the exhaust more than doubles a CO2-adsorbent's capacity, enabling 100% of the carbon to be captured while simultaneously reducing the size and cost of the system, according to ESG Camber's wholly-owned subsidiary has licensed the intellectual property associated with ESG's clean energy and carbon-capture system for exclusive use in Canada and for multiple locations in the U.S.

09:07 EDT Rumble launches partnerships with multiple exclusive brands - Rumble announced the launch of partnerships with three exclusive Rumble-branded products: Pawsitive, Be Naked, and 5G Free. Pawsitive features a variety of healthy pet foods, Be Naked is a brand that will focus on male health, and 5G Free will focus on electromagnetic field wellness. Together, these brands bolster a growing ecosystem that supports the parallel economy and aligns with Rumble's mission and values. These new Rumble-exclusive products can be purchased online at pawsitive.com, benaked.com, and 5gfree.com.

09:06 EDT Webster Financial appoints William Holland as next CFO - Webster Financial (WBS) announced its board of directors approved both the appointment of William Holland, as executive VP, finance of both the company and the bank, and the election of William Haas, as a new non-management member of the board of directors of the company and the bank. In addition, the board of directors also appointed Holland as the CFO for the company and the bank to be effective following current executive VP and CFO Glenn MacInnes' previously announced retirement, which is expected in August. At that time, MacInnes will assume an advisory role. Holland brings more than 20 years of strategic and financial experience to Webster, including most recently serving as CFO for First Republic Bank (FRCB) until May 2023.

09:06 EDT Edwards Lifesciences acquires early-stage TMVR company Innovalve, no terms - Edwards Lifesciences announced it has exercised its option to acquire Innovalve Bio Medical, an early-stage transcatheter mitral valve replacement TMVR company, following its initial investment in 2017. Since that time, Innovalve has demonstrated progress in its program with promising early clinical experience. Combined with Edwards' existing mitral innovations, the acquisition enhances the company's TMVR technologies to address large unmet structural heart patient needs and support sustainable long-term growth. Innovalve will join the transcatheter mitral and tricuspid therapies TMTT product group, led by corporate vice president, Daveen Chopra...The acquisition is expected to close by the end of 2024.

09:05 EDT PodcastOne signs Chris Kattan, Andy Bolduc, Jospeh Nunez to multi-year deal - PodcastOne (PODC), a subsidiary of LiveOne (LVO), announced that it has signed comedian and actor Chris Kattan to a multi-year contract for the exclusive sales and distribution rights for Kattan's debut podcast, Idiotically Speaking with Chris Kattan. The weekly comedy variety show podcast is set for a July 24, 2024 debut and upcoming guests include Saturday Night Live alum and fellow comedians Fred Armisen, Dana Carvey, Rachel Dratch, Tim Meadows, Bobby Moynihan, Chris Parnell and Cecily Strong. "PodcastOne is thrilled to welcome Chris, Andy and Joseph to the network. Chris' comic genius, his improvisational skills and his rapport with his co hosts on Idiotically Speaking are great additions to the roster of shows already part of our slate of programming. We know that listeners and advertisers will equally embrace this show with enthusiasm," said Kit Gray, President and Co-Founder of PodcastOne.

09:03 EDT Urgently secure roadside assistance contract renewal with global automotive OEM - Urgent.ly announced the renewal of its six-year customer partner relationship with a global automotive OEM, known for its focus on safety, quality and innovation. The renewed agreement extends this relationship to eight years and underscores Urgently's commitment to delivering significant customer value through exceptional service, cutting-edge technology and a prioritization of safety. "We are thrilled and honored to continue this enduring and successful partnership," said Matt Booth, Chief Executive Officer, Urgently. "We believe this renewal reflects the strength of our technology and the outstanding level of service we provide to our OEM customer partners and their customers. We value our sustained collaboration and look forward to continuing to deliver roadside assistance solutions that meet our partner's evolving needs." Under the renewed contract, Urgently will continue to power the automotive OEM's warranty-based roadside assistance program as well as its post-warranty roadside assistance membership plans in the U.S., Canada and Mexico. Urgently will also continue to provide assistance for operational, technical and mechanical breakdowns, as well as accident-related towing services.

09:02 EDT Arbor Realty reiterates 'confidence' in financials, business practices - The company said, "Following recent news reports, Arbor Realty Trust is issuing this announcement to reiterate that its financials and business practices have been and are compliant with all of its accounting and regulatory obligations. As it has throughout its history, Arbor continues to conduct its business operations and practices in the best interest of its shareholders and consistent with its obligations to its broader stakeholders. Arbor complies with all notice and disclosure obligations and other terms of its CLO agreements. Arbor also complies with all of its disclosure and reporting obligations, including those relating to its second quarter activities. Arbor's annual financial statements are audited by an independent auditor and its quarterly reports are also reviewed by its external auditor. Arbor stands behind its accounting, as well as its originating and investing practices. Further, Arbor's policy and practice is to cooperate with its regulators. Arbor looks forward to discussing its second quarter performance in its upcoming earnings call in early August."

09:02 EDT Safety Shot partners with KeHE Distributors to expand nationwide access - Safety Shot announced its strategic partnership with KeHE Distributors, a natural and organic, specialty, and fresh food distributor in North America. KeHE's impressive team of more than 6,800 employee-owners and a 19-distribution center network across North America deliver Safety Shot's formula to new retail locations across the U.S. This follows recent partnership announcements with Atlantic Beverage Distributors and Prime CSB to expand access for Safety Shot across the country.

08:48 EDT Crown Electrokinetics awarded an additional segment on Nevada project - Crown Electrokinetics has been awarded an additional segment under its current agreement in Nevada which commenced in May. This work complements, and is an extension of, an ongoing large backbone long haul fiber project that includes horizontal drilling and plowing work. Crown previously received two "clusters" of the project which are expected to generate approximately $5.7M in gross revenues.

08:41 EDT Modular Medical announces proof-of-concept study using MODD1 Platform - Modular Medical announced a proof-of-concept study with Gubra in a high-fat, diet-induced obese mouse model to explore the potential future use of the MODD1 pump platform to assist patients who struggle with tolerability, inconsistent efficacy, and cost of long acting GLP-1 therapies. "A recent study published by Blue Health Intelligence using data from a national dataset of private insurers found that about half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately 30% discontinuing in the first four weeks," commented Jeb Besser, CEO of Modular Medical. "These discontinuations appear to be due to a combination of tolerability, cost, and inconsistent efficacy. We suspect that short-acting peptides may mitigate many of these side effects and dosage swings by better modulating dosage, but these therapies have generally been abandoned as "too difficult to use" because they required multiple doses per day to be effective. We see the potential for such dosing regimes to be greatly simplified and even improved by the use of pump technology to provide both a basal dose and boluses to control hunger. Using Gubra's gold-standard DIO mouse model, MODD will seek to determine whether an existing FDA approved, short-acting peptide delivered from a pump platform can provide a more personalized and more tolerable solution for patients who found long acting GLP-1 drugs too difficult to tolerate, while delivering comparable glycemic control and weight loss, specifically for people with type 2 diabetes and obesity."

08:39 EDT Macy's to terminate discussions with Arkhouse Management, Brigade Capital - Macy's announced that, following months of engagement with Arkhouse Management, and Brigade Capital Management, its board of directors has unanimously determined to terminate discussions with Arkhouse and Brigade that have failed to lead to an actionable proposal with certainty of financing. The company said that the board intends for the management team to return its full focus to enhancing shareholder value through the execution of the Company's "A Bold New Chapter" strategy. Macy's said, "The Macy's, Inc. Board and management team have engaged in good faith with Arkhouse and Brigade for more than seven months since their initial outreach in December 2023 expressing interest in acquiring the Company. In March 2024, the Company entered into a confidentiality agreement with Arkhouse and Brigade to facilitate a due diligence process, given they had increased their proposal to $24.00 per share (from the initial $21.00 proposal) and indicated a willingness to increase this price further upon access to customary diligence, potentially to an amount that the Board could consider compelling. The Company has since expended hundreds of hours addressing Arkhouse and Brigade's extensive diligence requests, facilitating diligence meetings with multiple members of the Company's senior management as well as its financial and real estate advisors and providing thousands of documents with a level of detail that went well beyond what is customarily required to obtain financing for a public company acquisition, such as providing complete store-by-store P&L's and full-form leases for each Macy's, Bloomingdale's and Bluemercury location. The Company also permitted Arkhouse and Brigade to contact - and share confidential information with - over a dozen credible financing sources. In May 2024, the Company and Arkhouse and Brigade mutually agreed to a timetable for them to deliver a fully financed and actionable proposal to Macy's, Inc. The Company formally requested two items be delivered by June 25, 2024: 1) the best purchase price per share that Arkhouse and Brigade were prepared to pay to acquire the Company, and 2) fully negotiated commitment papers for all the debt and equity needed to finance the revised proposal, subject only to the negotiation of definitive documentation and customary confirmatory due diligence. On June 26, 2024, rather than delivering a definitive, fully financed and actionable proposal, Arkhouse and Brigade submitted a response they characterized as a "check in" letter expressing an interest in acquiring all of the outstanding shares of the Company for $24.80 per share in cash, which is within a range the Board had previously communicated to Arkhouse and Brigade was not compelling. Further, the financing papers that accompanied the "check in" letter were insufficient to give the Board confidence that a fully committed, financed and viable offer could be attained within any reasonable period of time - and necessitated bearing an unacceptable lack of certainty for the Company and its shareholders. More specifically, Arkhouse and Brigade submitted highly conditional and unsigned drafts of financing commitment letters, subject to numerous conditions, including, in certain cases, diligence on Arkhouse and Brigade themselves. Notwithstanding the Company's financial advisors making it clear that "enterprise level" financing commitment papers would be required (as is customary for public transactions in the sector), Arkhouse and Brigade delivered "asset-based" financing commitment papers tied to the valuation of the Company's owned real estate, and subject to appraisals, credit rating outcomes, and loan-to-value thresholds. Finalizing and funding these commitment letters would require lengthy additional diligence, including independent, third-party appraisals of over 140 of the Company's individual store and distribution center locations." Following a careful review of the "check in" letter and related materials in consultation with its independent legal and financial advisors, the board unanimously determined that the latest Arkhouse and Brigade proposal remains non-actionable and fails to provide compelling value to Macy's, Inc. shareholders.

08:36 EDT Macy's to terminate discussions with Arkhouse Management, Brigade Capital - Macy's announced that, following months of engagement with Arkhouse Management, and Brigade Capital Management, its board of directors has unanimously determined to terminate discussions with Arkhouse and Brigade that have failed to lead to an actionable proposal with certainty of financing. The company said that the board intends for the management team to return its full focus to enhancing shareholder value through the execution of the Company's "A Bold New Chapter" strategy. Macy's said, "The Macy's, Inc. Board and management team have engaged in good faith with Arkhouse and Brigade for more than seven months since their initial outreach in December 2023 expressing interest in acquiring the Company. In March 2024, the Company entered into a confidentiality agreement with Arkhouse and Brigade to facilitate a due diligence process, given they had increased their proposal to $24.00 per share (from the initial $21.00 proposal) and indicated a willingness to increase this price further upon access to customary diligence, potentially to an amount that the Board could consider compelling. The Company has since expended hundreds of hours addressing Arkhouse and Brigade's extensive diligence requests, facilitating diligence meetings with multiple members of the Company's senior management as well as its financial and real estate advisors and providing thousands of documents with a level of detail that went well beyond what is customarily required to obtain financing for a public company acquisition, such as providing complete store-by-store P&L's and full-form leases for each Macy's, Bloomingdale's and Bluemercury location. The Company also permitted Arkhouse and Brigade to contact - and share confidential information with - over a dozen credible financing sources. In May 2024, the Company and Arkhouse and Brigade mutually agreed to a timetable for them to deliver a fully financed and actionable proposal to Macy's, Inc. The Company formally requested two items be delivered by June 25, 2024: 1) the best purchase price per share that Arkhouse and Brigade were prepared to pay to acquire the Company, and 2) fully negotiated commitment papers for all the debt and equity needed to finance the revised proposal, subject only to the negotiation of definitive documentation and customary confirmatory due diligence. On June 26, 2024, rather than delivering a definitive, fully financed and actionable proposal, Arkhouse and Brigade submitted a response they characterized as a "check in" letter expressing an interest in acquiring all of the outstanding shares of the Company for $24.80 per share in cash, which is within a range the Board had previously communicated to Arkhouse and Brigade was not compelling. Further, the financing papers that accompanied the "check in" letter were insufficient to give the Board confidence that a fully committed, financed and viable offer could be attained within any reasonable period of time - and necessitated bearing an unacceptable lack of certainty for the Company and its shareholders. More specifically, Arkhouse and Brigade submitted highly conditional and unsigned drafts of financing commitment letters, subject to numerous conditions, including, in certain cases, diligence on Arkhouse and Brigade themselves. Notwithstanding the Company's financial advisors making it clear that "enterprise level" financing commitment papers would be required (as is customary for public transactions in the sector), Arkhouse and Brigade delivered "asset-based" financing commitment papers tied to the valuation of the Company's owned real estate, and subject to appraisals, credit rating outcomes, and loan-to-value thresholds. Finalizing and funding these commitment letters would require lengthy additional diligence, including independent, third-party appraisals of over 140 of the Company's individual store and distribution center locations." Following a careful review of the "check in" letter and related materials in consultation with its independent legal and financial advisors, the board unanimously determined that the latest Arkhouse and Brigade proposal remains non-actionable and fails to provide compelling value to Macy's, Inc. shareholders.

08:36 EDT Astrana Health and Anthem Blue Cross partner in California - Astrana Health and Anthem Blue Cross, one of California's largest health insurers, and Allied Pacific IPA, part of Astrana Health, an independent physician association serving the California community since 1992, announced a new partnership aimed at improving access to high-quality healthcare for their shared members. Astrana Health and Anthem Blue Cross will collaborate to expand access to high-quality patient care in previously underserved member communities. Astrana will open and manage clinics providing care exclusively for Anthem Blue Cross and Allied Pacific IPA members. In conjunction, Astrana and Anthem Blue Cross have opened their first collaborative care clinic in Whittier, California.

08:35 EDT Kolibri Global Energy announces shareholder loyalty campaign - Kolibri Global Energy announced the launch of a shareholder loyalty campaign in partnership with TiiCKER, the world's first and largest shareholder loyalty and engagement platform, and B2i Digital, a digital marketing powerhouse specializing in direct communication with retail investors. For the first time, Kolibri will be able to reach its retail investor audience through a perk program hosted on TiiCKER's web-based and mobile app platforms, as well as digital marketing campaigns directed at B2i's community of over 850,000 investors. This combination will offer Kolibri a comprehensive suite of services to verify, educate and reward its retail investors.

08:33 EDT Cematrix announces uplisting to TSX, new ticker symbol - CEMATRIX announced the Company is uplisting from the TSX Venture Exchange to the Toronto Stock Exchange. Concurrent with the uplisting, the Company is changing its ticker symbol to CEMX. It is expected that at the market open on July 16, 2024, the company's common shares will cease trading on the TSXV and begin trading on the TSX under the ticker symbol CEMX. No action is required by shareholders to continue trading their common shares as a result of the uplisting, or the change in ticker symbol.

08:33 EDT Trinity Capital invests $15M in Velentium - Trinity Capital announced the commitment of $15M in growth capital to Velentium, a professional engineering firm that specializes in the design and manufacture of innovative medical devices. Based in Houston, Velentium designs, develops, manufactures, and provides post-market support for medical devices. Velentium recently moved into their new corporate headquarters in Houston, which provides improvement in their manufacturing capacity to support their contract manufacturing business. The new debt facility from Trinity will facilitate Velentium's continued growth.

08:33 EDT Complete Solaria acquires selected assets of Core Energy - Complete Solar has acquired selected assets of Core Energy, a Logan, Utah solar engineering, procurement and construction (EPC) firm, and hired its 37 employees, including the CEO, Cole Farmer, an industry veteran who will run Sales and Marketing for the combined company. Due to tight cost management and merit-based retention, Complete Solar's headcount will increase from 106 to only 113 because of the acquisition. Cole Farmer has worked in Utah's "Solar Valley" since joining Vivint in 2014. His most relevant experience came at Legacy Power, a large, private solar sales company, where he worked before starting Core Energy in 2019. Our industry is divided into solar sales companies, which typically sell systems door-to-door for about 30% of revenue and EPC companies, like Complete Solar, that install the systems. Cole grew Core Energy's revenue to $143 million in the 2022 solar boom, before it dropped to its current annualized revenue of $22 million due to the solar downturn triggered by rate changes to California's Net Energy Metering, which lowered the payment for home solar power delivered to the grid by 75%.

08:31 EDT NNN Reit raises quarterly dividend 2.7% to 58c per share - The Board of Directors of NNN REIT announced a quarterly dividend of 58c per share payable August 15 to shareholders of record as of July 31. The 2.7% increase in the quarterly dividend marks the 35th consecutive annual dividend increase. NNN is one of only three publicly traded REITs to have increased its annual dividend for 35 or more consecutive years.

08:31 EDT Actelis Networks receives software, service contract renewal of $1.5M - Actelis Networks announced that it has received an approximately $1.5M software and service order from a major customer based in North America. Recently, Actelis announced significant critical IoT infrastructure wins in the military and energy sectors as well as in the intelligent transportation space. This new order showcases Actelis' ability to support critical large-scale networks with a powerful management system and first-class technical support. This agreement provides software and support for a large network across several states. The core of the agreement is licensed access to Actelis' Element Management Software System, a highly scalable platform that provides a host of tools to remotely and securely monitor and manage network devices, and remotely provision new devices for fast deployment. Actelis' EMS solution enables fast "time to service" with automated configuration and software upgrades, as well as offering robust configuration management, helping customers easily manage inventory, firmware, and software backups. EMS also gives customers all the tools they need to monitor the status of their networks including real-time event notifications, email alerts, and a wide range of reports.

08:18 EDT Catheter Precision announces effectiveness of 1-for-10 reverse stock split - Catheter Precision announced that its previously announced 1-for-10 reverse stock split of its common stock became effective at 12:01 A.M. Eastern Time, on July 15, 2024. The Company's common stock will continue to be traded on the NYSE American under the symbol "VTAK" and will begin trading on a split-adjusted basis when the market opens on July 15, 2024. The new CUSIP number for the Company's common stock following the reverse stock split will be 74933X 609. Pursuant to the reverse stock split, every 10 shares of the Company's issued common stock will be converted automatically into one issued share of common stock without any change in the par value per share. Stockholders holding shares through book entry on the Company's records will have their shares automatically adjusted to reflect the 1-for-10 reverse stock split. It is not necessary for stockholders holding shares of the Company's common stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish.

08:16 EDT Ocean Power awarded contract for delivery of AI capable Merrows buoy - Ocean Power Technologies announced it has been awarded a contract for immediate delivery of a PowerBuoy equipped with Merrows, its Artificial Intelligence capable Maritime Domain Awareness Solution, in the Midde East. This contract will generate revenues in the current quarter. Due to the confidential nature of the award, details are not being disclosed. Philipp Stratmann, CEO and President of OPT, expressed his enthusiasm about this revenue generating contract, stating, "We are continuing to grow our business across all our solutions, WAM-Vs and PowerBuoys. We believe this shipment for a solar and wind powered system highlights our ability to service almost all marine environments across the globe. Offering proven technology solutions makes it easy for our potential customers to integrate additional WAM-Vs and PowerBuoys into their operations and to put ocean intelligence into their hands."

08:14 EDT Checkpoint Therapeutics, GC Cell advance collaborative cancer research - GC Cell and Checkpoint Therapeutics have announced a collaboration to explore the combined therapeutic potential of cosibelimab, Checkpoint's anti-PD-L1 antibody with dual mechanism of action, with GC Cell's Immuncell-LC, an innovative autologous Cytokine Induced Killer T cell therapy composed of cytotoxic T lymphocytes and natural killer T cells. This collaboration will initially focus on conducting in vitro combination studies to evaluate the synergistic effects of these two therapies on cancer cell destruction. Positive preliminary data from these studies could potentially pave the way for future in vivo research and clinical studies. James Oliviero, CEO of Checkpoint Therapeutics, concurred: "Both cosibelimab, with its dual mechanism of action, and Immuncell-LC show great promise as potential immuno-oncologic therapies. We are pleased to work in collaboration with GC Cell to determine if using the two therapies in combination may offer even greater potential benefits than being used singly."

08:13 EDT Autonomix enters definitive agreement to license IP from RF Innovations - Autonomix Medical has entered into a definitive agreement with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property to its Apex 6 Radiofrequency Generator. The Apex 6 Generator is an FDA-cleared ablation technology designed to lesion neural tissue for pain management in the peripheral nervous system. The transaction is expected to close before the end of July 2024. The transaction, for 250,000 shares of common stock, grants Autonomix a perpetual non-exclusive worldwide and royalty-free license of the Apex 6 Generator intellectual property. Autonomix plans to utilize the technology in its strategic therapeutic areas to drive value across its pipeline. To facilitate equipment development, activities will begin immediately with RF Innovations manufacturing partner who will be incorporated into Autonomix's manufacturing supply chain.

08:12 EDT Genius Group announces $22M 'Genius Nation' contract with Kazakhstan government - Genius Group announced that it has secured and completed Phase 1 of a $22 million 'Genius Nation' contract with the Government of the Republic of Kazakhstan, enabling the development of a Sovereign AI in the country. The three year contract - secured by Genius Group subsidiary Prime Source with the Ministry of Digital Development of the Republic of Kazakhstan - is to centralize the nationwide supply and maintenance of databases for Kazakhstan's state bodies, enabling sovereign AI development. Eugene Sherbinin, CEO of Prime Source - a Genius Group Company, said: "This contract with the Ministry of Digital Development was won by Genius as part of a nationwide competition, following up on several other recent wins as we continue to fortify our reputation as a leader in delivering AI solutions nationwide. We have successfully completed the first phase of delivery and are now entering the second phase of fulfillment. We are excited to be a part of Kazakhstan's vision of becoming a leading AI nation."

08:11 EDT Lenz Therapeutics announces $30M investment from Ridgeback Capital - LENZ Therapeutics announced that it has entered into a stock purchase agreement with Ridgeback Capital Investments L.P. for a $30 million private investment in public equity common stock financing. "We appreciate the significant support and confidence that Ridgeback Capital is showing in LENZ and are pleased to have access to this additional capital, which further strengthens our Balance Sheet as we aim to make LNZ100 a potentially best-in-class therapeutic option for the treatment of presbyopia," said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. "With our strong Phase 3 CLARITY data in hand and impressed by the excitement from KOLs that studied LNZ100, we are looking forward to upcoming milestones, including the submission of our NDA for LNZ100 mid-year 2024 and turning our full focus towards preparing for the potential approval and commercialization of LNZ100".

08:10 EDT Milestone Pharmaceuticals appoints Duty, Saik to board of directors - Milestone Pharmaceuticals (MIST) announced steps to refresh its Board of Directors. Stuart Duty and Andrew Saik have been appointed to its Board, effective immediately, and will stand for election at the Company's 2024 Annual Meeting of Shareholders. The Company will appoint a third independent director to its Board in the near term. In conjunction with the announcement, the Company entered into a Cooperation Agreement with Alta Fundamental Advisers, one of the Company's shareholders. Duty has over 30 years of experience in investment banking and operations primarily in the biotechnology and specialty pharmaceuticals sectors. Most recently, he served as a Senior Managing Director at Guggenheim Securities, LLC from 2012 to 2023 where he advised senior executives and boards on a range of financing activities and strategic transactions. Saik has over 25 years of accounting and finance experience, including as Chief Financial Officer of biopharmaceutical companies Arvinas (ARVN).

08:09 EDT American Vanguard CEO Eric Wintemute concludes his position - American Vanguard reported that its chairman and CEO, Eric Wintemute, concluded his position as CEO, effective July 12. The terms of his departure are set forth in the transition agreement dated July 3. Going forward, Wintemute will continue to serve as chairman of the board and will provide consulting services to the company on a part-time basis, if needed.

08:07 EDT Eastern Bankshares merges with Cambridge Bancorp, David Rosato named CFO - Eastern Bankshares (EBC) announced the closing of its merger with Cambridge Bancorp (CATC) , the parent company of Cambridge Trust Company. The all-stock transaction was originally announced on September 19. "We are excited to have successfully completed Eastern's merger with Cambridge Trust and in doing so, to strategically solidify Eastern's position as Greater Boston's leading local bank and Cambridge Trust Wealth Management as the largest bank-owned independent investment advisor in Massachusetts," said Bob Rivers, Executive Chair and Chair of the Board of Directors of Eastern Bankshares, Inc. and Eastern Bank. "Our focus remains on creating value through high quality banking and wealth products and solutions. We thank the extraordinary employees from both companies for helping to make this transaction possible, and extend a warm welcome to our new colleagues, customers and shareholders." The conversion of Cambridge Trust banking products and services to Eastern Bank's systems occurred over the weekend of July 12... The conversion of Eastern Wealth Management customers to Cambridge Trust Wealth Management's systems is expected to occur later this year...As previously announced and upon closing of the Merger, Denis Sheahan, Chairman, President and CEO of Cambridge, has become Chief Executive Officer of Eastern and Eastern Bank, and has joined Eastern's Boards of Directors. Quincy Miller, in addition to his previous roles as President of Eastern and Vice Chair and President of Eastern Bank, has been promoted to Chief Operating Officer. Both Mr. Sheahan and Mr. Miller will report directly to Bob Rivers, who will remain Eastern's principal executive officer.

08:06 EDT Integra LifeSciences provides update plans for manufacturing facility in MA - Integra LifeSciences is announcing its plans to restart the manufacture of PriMatrix and SurgiMend at its new manufacturing facility in Braintree, Massachusetts, MA. The Company expects to operationalize this new facility in the first half of 2026. Since receiving the third-party audit findings for its Boston, Massachusetts, manufacturing facility in March, the Company has been thoroughly reassessing its plans and timeline to resume the manufacture of PriMatrix and SurgiMend at this site. In parallel, the Company has been furthering its plans to complete the construction and operationalization of its new state-of-the-art tissue manufacturing facility in Braintree. "Given the advantages of the Braintree facility and the challenges of the Boston facility, the decision to consolidate our efforts at our new Braintree location enables us to focus our resources in one location. This represents a minimal difference in timing compared to restarting in our existing Boston facility, while limiting execution risk," said Robert Davis, Jr., executive vice president and president of Integra's Tissue Technologies division.

08:05 EDT Oncternal completes enrollment, dosing in Phase 1/2 study of ONCT-534 - Oncternal Therapeutics announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its Phase 1/2 study of ONCT-534 for the treatment of patients with metastatic castration-resistant prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors. An initial update on ONCT-534 safety and efficacy based on prostate-specific antigen levels from this study is expected in the third quarter of 2024 and will include data from this 1200 mg dose cohort. "We are encouraged by the rapid enrollment in the dose escalation portion of our Phase 1/2 study with ONCT-534. The drug has been well tolerated, with no dose limiting toxicities observed to date. Patient demand continues to be strong," said Salim Yazji M.D., Chief Medical Officer at Oncternal Therapeutics. "We are looking forward to sharing initial safety and efficacy data soon, which will include a larger, more robust set of clinical and biomarker results, as well as longer follow-up from the earlier dosing cohorts."

08:04 EDT Gorilla appoints Keith Levy to board of directors - Gorilla Technology Group Inc. (GRRR) announced Keith Levy, former Head of Corporate Derivatives Trading for Bank of America (BAC), has joined Gorilla's Board of Directors.

08:03 EDT Arq secured material incremental contracted volume for supply of GAC - Arq announced it has secured material incremental contracted volume for the supply of granular activated carbon, GAC, to be produced at its strategic Red River facility. For competitive reasons, the Company will not be sharing the sectors or volumes of all associated customers. Total contracted GAC demand now stands, when fully scaled up to ultimate run-rate requirements, at 13 million pounds per annum, representing 52% of Arq's expanded nameplate capacity of 25 million pounds per annum at its strategic Red River activated carbon manufacturing facility. Construction at the Red River facility remains on schedule for first commercial production by year-end 2024. Bob Rasmus, CEO of Arq, remarked, "Every contract we secure further validates our GAC products and strategy. I remain incredibly proud of our team's efforts to drive sales and collaborate with partners who show their confidence by committing to our GAC solutions. Our superior products, valuable environmental technology and wide range of industry applications continue to receive strong recognition. We believe the market has a limited supply of high-quality, fully integrated and domestically procured GAC - securing contracts representing more than 50% of Red River's capacity with nearly six months to production clearly supports this view."

08:01 EDT NV5 Global awarded $7M for electrical transmission undergrounding - NV5 Global announced that it has been awarded a one-year, $7 million contract to provide project oversight, testing, and inspection during the construction of a new 230 kilovolt underground transmission line in Northern California. "The demand for electricity and the strain on the nation's electrical grid infrastructure is growing due to electrification initiatives and expansion of high-energy facilities, such as data centers," said Dickerson Wright, PE, Executive Chairman of NV5. "NV5's industry-leading expertise in electrical grid reliability is in high demand, and we are well-positioned to drive accelerated organic growth in our utility services business."

07:36 EDT Enthusiast Gaming secures $20M term loan - Enthusiast Gaming Holdings has received a $20 million four-year non-revolving term loan. The financing was arranged pursuant to a credit agreement with lenders led by Beedie Investments, which is also the administrative and collateral agent.

07:35 EDT MediWound receives $15M investment from Molnlycke Health Care - MediWound announced today an investment of $15M from Molnlycke Health Care, a MedTech company specialising in solutions for wound care and surgical procedures, through a definitive share purchase agreement in a private investment in public equity. Molnlycke and MediWound have also entered into a collaboration agreement. Under this agreement, Molnlycke is granted specific rights, including having a representative attend meetings of MediWound's R&D Committee and will also be able to participate in potential strategic partnership discussions and M&A processes under certain circumstances.

07:33 EDT I-Mab announces leadership transitions - I-Mab has appointed Wei Fu as the Chairman of the Board of Directors. He succeeds Pamela Klein, who steps down from I-Mab's Board of Directors and the Interim Chairperson position. Wei Fu has served as a member of the I-Mab Board of Directors since June 2018 and is CEO of CBC Group, a healthcare asset management firm and the founding and largest shareholder of I-Mab. In addition, Raj Kannan intends to leave his role as CEO and as a member of the Board, effective July 15. Kannan will stay as an advisor of the company until July 31 to assist with the transition. Sean Xi-Yong Fu has assumed the role of Interim CEO and a member of the Board of Directors, effective July 15. In addition to being Interim CEO and Director of I-Mab, Sean Fu is also an Operating Partner of ABio-X, an incubation platform for life sciences companies. Before joining ABio-X, Fu was co-founder and CEO of RVAC Medicines, an mRNA platform company. Previously, Fu worked at Merck & Co. for 15 years. In addition to these leadership transitions, the Company also announced certain changes to the composition of the Board of Directors and its committees: the resignations of Ruyi He and Professor Rong Shao as Directors, and the appointments of Wei Fu and Conor Chia-hung Yang as new members of the compensation committee.

07:32 EDT OptimizeRx announces results on Dynamic Audience Activation Platform - OptimizeRx announced the results of an internal marketing study demonstrating that the Company's predictive marketing technology, the Dynamic Audience Activation Platform, can deliver superior program results for life sciences brands looking to reach and engage audiences that are complex to diagnose and treat. As routine diligence, OptimizeRx monitors performance of all client programs with which we are engaged so we can study outcomes and better understand performance impact on our clients' ability to measure return on marketing investment. The client executed two distinct programs in the marketing campaigns, using different targeting methodologies, on the OptimizeRx point-of-care network comprised of over 300 electronic health record, ePrescribing, telehealth, and practice management contributors. In the first program, the targeting methodology was trigger-based which is considered the current gold standard in point-of-care messaging. Messages were delivered based on specific clinical attributes, such as an ICD-10 code, found within the patient chart of a native electronic medical record. After the 6-month trigger-based program was completed, the brand elected to launch an additional engagement program leveraging DAAP for the same MDD therapy. After just 3-months of the new campaign, an early results comparison revealed significant advantages of a predictive marketing approach for this hard-to-reach audience compared to the traditional trigger-based model: Enhanced Audience Quality; Increased script Lift: DAAP delivered 33% higher script lift per HCP per month ; Improvement in ROI

07:29 EDT Goldman Sachs increases quarterly dividend to $3.00 per share in Q3 - On July 12, 2024, the Board of Directors of The Goldman Sachs Group, Inc. approved a 9% increase in the quarterly dividend to $3.00 from $2.75 per common share. The dividend will be paid on September 27, 2024 to common shareholders of record on August 30, 2024.

07:23 EDT Lupin sells U.S. Commercial Women's Health Specialty Business to Evofem - Lupin announced it has divested its U.S. Commercial Women's Health Specialty Business to Evofem Biosciences. Lupin's U.S. Commercial Women's Health Specialty Business is primarily focused on commercializing SOLOSEC 2g oral granules. This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis and trichomoniasis, two common sexual health infections. Under the terms of the deal, Lupin can receive a potential total consideration of up to $84M based on future contingent milestones.

07:12 EDT Nutriband receives notice of allowance for U.S. trademark for AVERSA - Nutribandreceived a Notice of Allowance from the United States Patent and Trademark Office on July 9, 2024, for trademark application Serial Number 98117984, covering the mark "AVERSA." The Notice of Allowance signifies that the USPTO is expected to grant a trademark registration for this application following the completion of administrative processes. The AVERSA trademark is integral to Nutriband's platform technology which can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Nutriband's lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system. Nutriband, in partnership with Kindeva Drug Delivery, is progressing towards completing the scale-up of the commercial manufacturing process for AVERSA Fentanyl. This partnership has successfully moved from a feasibility agreement to a commercial development and clinical supply agreement aimed at manufacturing product for the upcoming human abuse potential clinical study. This study is crucial for the New Drug Application that Nutriband plans to submit to the FDA. Upon completion of the commercial manufacturing process, Nutriband will file an Investigational New Drug application with the FDA. This filing will precede the pivotal laboratory and clinical evaluations needed to demonstrate the abuse-deterrent properties of AVERSA Fentanyl, in line with FDA Guidance. The IND will include comprehensive chemistry, manufacturing, and controls information and the clinical study protocol for the human abuse potential study. The pivotal clinical study will involve a randomized, double-blind, placebo-controlled, and positive-controlled crossover design, comparing AVERSA Fentanyl to a currently marketed fentanyl patch without abuse-deterrent technology. This human abuse potential study will assess the drug's "liking" among recreational users, which is predictive of the likelihood of abuse. Preliminary studies have shown that AVERSA technology is highly resistant to physical and chemical manipulation, reinforcing its potential effectiveness as an abuse deterrent.

07:09 EDT GHK Capital complees sale of Supreme Cabinerty Brands to MasterBrand - GHK Capital Partners recently completed the sale of Supreme Cabinetry Brands to MasterBrand for $520 million in cash. Supreme, based in Howard Lake, MN, is one of the largest manufacturers of premium residential kitchen and bath cabinetry in the U.S. Supreme was acquired by GHK in October 2019.

07:05 EDT Lifeist Wellness announces Mika offers full product catalog on Amazon.com - Lifeist Wellness (LFSWF) reports that its U.S. biosciences subsidiary Mikra Cellular Sciences now offers its full product catalog on Amazon.com (AMZN) with Prime Shipping. "We're pleased to announce that all Mikra products are now available on Amazon.com with Prime Shipping," said Andrea Judge, CEO of Mikra. "In conjunction with our participation in Prime Days, we're also about to unveil our big summer sale across the full product catalog."

07:04 EDT MediWound announces $25M strategic private placement - MediWound entered into a definitive share purchase agreement with several new and existing investors, including Molnlycke Health Care. The agreement includes the sale and purchase of 1,453,488 shares of the Company's ordinary shares, each with a par value NIS 0.07, in a private investment in public equity. The purchase price is set at $17.20 per share. The gross proceeds from the PIPE Offering are $25 million. MediWound plans to use the net proceeds to advance EscharEx pre-commercial activities, expedite the development of large-scale manufacturing capabilities specifically for EscharEx, and support general corporate purposes. The PIPE Offering is expected to close within several days, subject to satisfaction of customary closing conditions. Concurrently with the PIPE Offering, MediWound and Molnlycke entered into a collaboration agreement to strengthen their partnership. Under the key terms of this agreement, Molnlycke is granted specific rights, including a representative to attend meetings of the Company's R&D Committee. Additionally, Molnlycke will be able to participate in potential strategic partnership discussions and M&A processes under certain circumstances. The Collaboration Agreement also contains a stand-still clause that limits Molnlycke's ownership to no more than 9.99% of the Company's issued and outstanding Ordinary Shares. The Company also entered into a registration rights agreement with several investors named in the Share Purchase Agreement, providing them with customary registration rights in connection with the Ordinary Shares.

07:04 EDT ANI Pharmaceuticals announces FDA approval, launch of L-Glutamine oral powder - ANI Pharmaceuticals announced that following final approval from the U.S. Food and Drug Administration, FDA, for its Abbreviated New Drug Application, ANDA, the Company launched L-Glutamine Oral Powder. ANI's L-Glutamine Oral Powder is the generic version of the reference listed drug, RLD, Endari. "The approval and launch of L-Glutamine Oral Powder, the first AA-rated approved generic to Endari, continues to demonstrate the strong capabilities and execution of our R&D team. We remain focused on ensuring that patients in need, and the providers who care for them, have access to our high-quality therapeutics," stated Nikhil Lalwani, President and Chief Executive Officer of ANI.

07:03 EDT Freightos reports key performance indicators for Q2 - Freightos reported preliminary second quarter 2024 Key Performance Indicators. In Q2 2024, Freightos continued to progress toward its long-term growth objectives. The company facilitated 316.5 thousand transactions, representing a year-over-year growth of 32%, surpassing management expectations for the quarter and exceeding the long term target of 20-30% annual transaction growth rate. This significant transaction growth highlights the growing adoption of digital solutions in the freight industry. Gross Booking Value for Q2 2024 grew 31% compared to the same quarter last year, consistent with the growth of Transactions. Management had anticipated that GBV growth may lag at 15-18% growth, due to softer market prices. However, due to the ongoing Red Sea crisis, average prices did not drop and so GBV growth was consistent with Transaction growth. In Q2 2024, Freightos expanded its Carrier network to 51 carriers, up from 37 in Q2 2023. Additionally, the count of Unique Buyer Users rose to approximately 19 thousand, reflecting a 16% increase from Q2 last year.

07:02 EDT Phoenix Motor delivers five 40' ZX5 battery electric buses to UCI - Phoenix Motor delivered five 40' ZX5 battery electric buses in May for the University of California, Irvine, or UCI. UCI has had an electric fleet since January 2018. Since then, UCI has added 25 buses to their fleet, and logged 1,183,210 miles.

07:02 EDT Sol-Gel Technologies announces CEO Seri-Levy to step down - Sol-Gel Technologies announced that the Chief Executive Officer, Dr. Alon Seri-Levy, has recently advised the Sol-Gel Board of Directors of his desire to step down from his position as CEO and member of the Board. The Company and Dr. Seri-Levy have agreed on the terms of Dr. Seri-Levy's separation from the Company and should these be approved by the Company's shareholders as required by Israeli law, Dr. Seri-Levy will step down from his positions as CEO and director effective as of December 31, 2024. At such time, Dr Seri-Levy will continue to provide his expertise to the Company through a one-year consulting agreement. In addition, effective July 12, 2024, Eyal Ben-Or, who served as the Company's Director of Finance as of September 2022 and before that as Corporate Controller since May 2017, will assume the role of Chief Financial Officer.

06:56 EDT Site Centers announces 1-for-4 reverse stock split - Site Centers has unanimously approved a one-for-four reverse stock split of the company's common shares. The reverse stock split was authorized by the company's shareholders at the annual meeting of shareholders held on May 8. As a result of the reverse stock split, every four of the company's issued common shares will be exchanged for one of the company's common shares. The company currently anticipates that its common shares will begin trading on a split-adjusted basis on the NYSE at the opening of trading on August 19.

06:54 EDT Pentair, Minneapolis-St. Paul Airport collaborate in waste reduction - Pentair and Minneapolis-St. Paul International Airport, or MSP, announced a new collaboration to sustainably deliver high-quality drinking water while reducing the need for single-use plastic water bottles for the millions of travelers that visit and fly through the MSP international hub each year. As the Official Water Sponsor of MSP, Pentair is working to help the airport promote sustainability through the installation of 10 HOPE Hydration HydroStations. The HydroStations are the first water refill stations of their kind at any airport worldwide. Using integrated IoT technology, the HydroStations at MSP track real-time impact data associated with the elimination of single-use plastics including plastic and carbon emissions savings, which will be displayed on each HydroStation.

06:47 EDT Scorpio Tankers provides update to its securities repurchase program - Scorpio Tankers recently repurchased 756,312 of its common shares in the open market at an average price of $78.07 per share under the 2023 Securities Repurchase Program. Since June 1, 2024, the company has repurchased an aggregate of 1,397,966 of its common shares in the open market at an average price of $78.16 per share. There is $140.7M available under the 2023 Securities Repurchase Program as of July 12.

06:36 EDT Franco-Nevada, Osisko Gold acquire gold stream from SolGold Cascabel project - Franco-Nevada (FNV) announced that its wholly-owned subsidiary, Franco-Nevada Barbados Corporation, or FNB, has acquired a gold stream from SolGold (SLGGF) with reference to production from the Cascabel project located in Ecuador. FNB has partnered with Osisko Gold (OR) Royalties' subsidiary, Osisko Bermuda, to provide a syndicated financing package on a 70%/30% basis. FNB will provide a total of $525M and Osisko a total of $225M of funding for a total $750M. FNB will provide $70M and Osisko $30 for a total of $100 in pre-construction funding available as three equal sized staged payments. The first tranche will be funded at closing with two further tranches, subject to development milestones. FNB will make $455M available and Osisko will make $195M available for a total of $650M towards construction once the project is fully funded and further derisked. Funding is subject to customary conditions including receipt of all material permits, a board approved construction decision and the balance of financing being available, including a minimum equity commitment. Cascabel is one of the largest copper-gold development projects in the world with total M&I Mineral Resource comprised of 3,735 million tons at 0.49% CuEq for 31.3M ounces of gold, 12.4M tons of copper, and 91.3M ounces of silver. Franco-Nevada intends to finance the transactions from cash on hand, with approximately $1.3B in cash and cash equivalents and $2.3B in available capital as at March 31.

06:18 EDT AstraZeneca completes acquisition of Amolyt Pharma - AstraZeneca announced the successful completion of the acquisition of Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. "The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline and expands on its bone metabolism franchise with the notable addition of eneboparatide, or AZP-3601, a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism. In patients with hypoparathyroidism, a deficiency in parathyroid hormone, or PTH, production results in significant dysregulation of calcium and phosphate, which can lead to life-altering symptoms and complications, including chronic kidney disease. This programme, together with Amolyt's talent, expertise and earlier pipeline, will enable Alexion's expansion into rare endocrinology." Under the terms of the definitive agreement, AstraZeneca has acquired all of Amolyt Pharma's outstanding shares for a total consideration of up to $1.05B, on a cash and debt free basis. This includes $800M upfront at deal closing, plus the right for Amolyt Pharma's shareholders to receive an additional contingent payment of $250M payable upon achievement of a specified regulatory milestone. AstraZeneca looks forward to welcoming the employees of Amolyt Pharma," the company stated.

06:15 EDT BlackRock reports Q2 net inflows $82B, positive across product types

06:15 EDT Apple jumps 2% to $235.42 after Loop upgrade, Morgan Stanley target hike

06:12 EDT Benitec Biopharma's BB-301 shows efficacy in Phase 1b/2a study of OPMD - Benitec Biopharma announced continued durable improvements in the radiographic assessments of swallowing efficiency and the subject-reported outcome instrument as assessed at the 180-day timepoint following the administration of the low-dose of BB-301 to the study's first subject treated in the BB-301 Phase 1b/2a study in Oculopharyngeal Muscular Dystrophy, or OPMD. BB-301 has been granted Orphan Drug designation by the FDA and EMA Committee for Orphan Medicinal Products. OPMD is a rare progressive muscle-wasting disease for which there is currently no effective drug therapy. The disease is characterized by swallowing difficulties, limb weakness and eyelid drooping. Benitec plans to provide additional analyses of the interim clinical study data at upcoming medical conferences and company-sponsored Research and Development-focused webcasts in 1Q25. The company is poised to dose the third subject in Q3 and remains on track to report additional interim clinical study results in 1Q25. At the 90-day post-dose assessment following the administration of the low-dose of BB-301, Subject 1 demonstrated improvements in key videofluoroscopic swallowing study assessments which correlated with the observation of similar levels of improvement in the Sydney Swallow Questionnaire vs. the pre-dose average values recorded for Subject 1 during the OPMD Natural History Study, indicating an improvement in swallowing function as reported by Subject 1. The post-dose average values for TPR remained meaningfully reduced. Regarding the BB-301 safety profile observed to date, acid reflux or heartburn has been reported previously in April 2024 at the time of the Research and Development Day webcast. No Serious Adverse Events have been observed for the two subjects that have received the low-dose of BB-301.

06:08 EDT BlackRock CEO says generated nearly $140B of total net inflows in 1H24 - Laurence Fink, Chairman and CEO: "BlackRock is executing on the broadest opportunity set we've seen in years, including in private markets, Aladdin, and whole portfolio solutions across both ETFs and active. At the same time, we are opening up meaningful new growth markets for our clients and shareholders with our planned acquisitions of Global Infrastructure Partners and Preqin. "BlackRock generated nearly $140 billion of total net inflows in the first half of 2024, including $82 billion in the second quarter resulting in 3% organic base fee growth. Organic growth was driven by private markets, retail active fixed income, and surging flows into our ETFs, which had their best start to a year on record. We are delivering growth with scale, reflected in a 12% increase to operating income and 160 basis points of margin expansion. "BlackRock has longstanding relationships with corporates and governments around the world as a long-term investor in public equity and debt. These relationships differentiate BlackRock as a capital partner in private markets, driving unique deal flow for clients. We have strong sourcing capabilities, and we are transforming our private markets platform to bring even more benefits of scale and technology to our clients. We are on pace to close our planned acquisition of Global Infrastructure Partners in the third quarter of 2024, which is expected to double private markets base fees and add approximately $100 billion of infrastructure AUM. And just a few weeks ago, we announced our agreement to acquire Preqin, a leading private markets data provider. "BlackRock is defining a unique, integrated approach to private markets - spanning investment, technology workflows and data. We believe this will deepen our relationships with clients, and deliver value for our shareholders through premium, diversified organic revenue growth. "Clients have always been at the center of our strategy. We will continue to innovate and evolve to deliver the outcomes and performance they need. We believe our momentum with clients will only accelerate from here, driving differentiated growth for our shareholders."

06:05 EDT BlackRock reports Q2 AUM $10.65T, up 13% y/y

05:57 EDT Trump Media shares jump 49% to $46.14 following Saturday's assassination attempt

05:23 EDT Rio Tinto, Ngarluma to progress renewable energy project - Ngarluma Aboriginal Corporation, or NAC, and Rio Tinto have agreed to pursue the development of an 80MW solar farm on Ngarluma Country, near Karratha, to supply renewable energy to the company's iron ore operations in Western Australia's Pilbara region. The solar farm is the first proposed project the Ngarluma people and Rio Tinto will pursue after a memorandum of understanding was signed to explore opportunities for renewable energy projects on Ngarluma Country. The project is expected to be located next to Rio Tinto's existing Yurralyi Maya Power Station near Karratha. This project has the potential to displace up to 11% of natural gas currently used for generation across Rio Tinto's integrated mining operations in the Pilbara, reducing Rio Tinto's emissions by up to 120kT CO2e per year once complete. A feasibility study is expected to be completed in early 2025, with commissioning in 2027, subject to relevant approvals and final investment decision. It is estimated that 600MW to 700MW of renewable energy will be required by 2030 to displace the majority of gas use across Rio Tinto's Pilbara power network, while additional renewable energy will be required to support widespread fleet electrification, which is expected after 2030.

05:14 EDT Nyxoah appoints Scott Holstine as chief commercial officer - Nyxoah announced the appointment of Scott Holstine as chief commercial officer. In this role, Holstine will lead the commercial operations of Nyxoah enabling a successful U.S. launch. Holstine brings over 26 years of experience in the medical device industry with a proven track record in U.S. product launches.

05:11 EDT Ericsson. Oppo sign multi-year global patent cross license agreement - Ericsson and Oppo have signed a multi-year global patent cross license agreement. This agreement includes a cross license covering patents essential to standards for cellular technologies, including 5G. Oppo, a smartphone vendor with sales in global markets, and presence in developing countries, will make royalty payments to Ericsson. In addition to a cross license, Oppo and Ericsson will conduct business cooperation on a number of projects related to 5G, including device testing, customer engagements and marketing activities. This agreement is in line with global practice where companies that provide products using cellular 3GPP standards such as 5G need a license agreement with patent holders in order not to infringe these patents, and also for patent holders to be compensated for their R&D investment. The financial benefit of this agreement was already reflected in Ericsson's Q2 financial results. Over several decades, Ericsson has been a contributor to 3GPP and to the development of global mobile standards.

05:04 EDT Nokia partners with Telecom Egypt to bring 5G technology to Egypt - Nokia announced a new partnership with Telecom Egypt to bring 5G technology to Egypt for the first time. The collaboration aims to revolutionize the country's telecom landscape by introducing the transformative power of 5G to cities including Alexandria, Aswan, Cairo, Giza, and Luxor. Nokia will provide its comprehensive AirScale portfolio to deliver an exceptional network experience to Telecom Egypt's customers including faster data speeds, enhanced performance, and capacity. Deployment will take place later this year. Under the agreement, Nokia will deploy 5G radio access network, or RAN, equipment from its AirScale portfolio, comprising baseband units and its latest generation of Massive MIMO radios. These solutions utilize Nokia's energy-efficient ReefShark System-on-Chip technology, delivering extensive 5G capacity and coverage as well as enabling easy deployments. Nokia will also offer various professional services, encompassing deployment, integration, and network optimization. Earlier this year, Telecom Egypt secured the country's first 5G license, which is valid for 15 years.